Background: Several imaging modalities are available for diagnosis of hepatocellular carcinoma (HCC).
H epatocellular carcinoma (HCC) is the most common primary malignant neoplasm of the liver, usually developing in persons with chronic liver disease. Worldwide, it is the fifth most common type of cancer and the third most common cause of death from cancer (1) . There were 25 000 deaths attributed to liver and intrahepatic bile duct cancer in the United States in 2011 (2). Common causes of HCC are hepatitis C virus infection, hepatitis B virus infection, and alcohol abuse, although a substantial proportion of cases have no identifiable cause (3-5).
Imaging modalities for HCC include ultrasonography, computed tomography (CT), and magnetic resonance imaging (MRI). Although CT and MRI provide higher-resolution images than ultrasonography, they are also more costly and, in the case of CT, are associated with radiation exposure (5) . Because HCC is typically a hypervascular lesion, CT and MRI are performed with arterial-enhancing contrast agents. Microbubbleenhanced ultrasonography can also be performed, although agents are not yet approved by the U.S. Food and Drug Administration for this purpose, and microbubbles are present in the liver for only a limited duration (6) . Other technical, patient, and tumor factors may also affect test performance (7) (8) (9) (10) (11) (12) .
This article reviews the test performance of ultrasonography, MRI, and CT for detection of HCC and for evaluation of focal liver lesions. This was conducted as part of a larger review commissioned by the Agency for Healthcare Research and Quality (AHRQ) on HCC imaging (13) . view in this article was performed in December 2014), the Cochrane Library, and Scopus. Additional studies were identified by reviewing reference lists and from peer review suggestions.
Study Selection
Two investigators independently evaluated each study at the title/abstract and full-text article stages to determine inclusion eligibility (Appendix Table 1 , available at www.annals.org). We included studies on the test performance of ultrasonography, CT, or MRI against a reference standard for detection of HCC in surveillance or nonsurveillance settings (for example, imaging performed in patients undergoing treatment for liver disease or in whom HCC was previously diagnosed) or for further evaluation of focal liver lesions. Reference standards were histopathologic examination based on explanted liver or nonexplant histologic specimens, imaging plus clinical follow-up (for example, lesion growth), or a combination of these.
We selected studies of ultrasonography (with or without contrast) and contrast-enhanced CT and MRI that met minimum technical criteria (non-multidetector or multidetector spiral CT, or 1.5-or 3.0-T MRI) (7) . We excluded studies published before 1998 and those in which imaging began before 1995, unless the imaging methods met minimum technical criteria; studies of MRI with contrast agents no longer commercially produced (for example, superparamagnetic iron oxide [ferumoxides or ferucarbotran] or mangafodipir); and studies of CT arterial portography, CT hepatic angiography, and intraoperative ultrasonography. We included studies of ultrasonography microbubble contrast agents because they are commercially available and commonly used outside the United States, and efforts to obtain approval from the U.S. Food and Drug Administration are ongoing (15) (16) (17) .
We excluded studies of diagnostic accuracy for non-HCC malignant lesions, including liver metastases. We included studies that reported results for HCC and cholangiocarcinoma together if cholangiocarcinoma lesions comprised less than 10% of the total. Studies on the accuracy of imaging for distinguishing HCC from a specific type of liver lesion (such as hemangioma or pseudolesion) and on the accuracy of imaging tests used in combination are addressed in the full report (13) .
We excluded studies published only as conference abstracts and included only English-language articles. The literature flow diagram is shown in Appendix Figure 1 (available at www.annals.org).
Data Abstraction and Quality Rating
One investigator abstracted details on the study design, dates of imaging and publication, patient population, country, sample size, imaging method and associated technical factors (Appendix Table 2 , available at www.annals.org), and results. Two investigators independently applied the approach recommended in the AHRQ Methods Guide for Medical Test Reviews to assess risk of bias as high, moderate, or low (18, 19) .
Data Synthesis
We conducted meta-analysis with a bivariate logistic mixed random-effects model that incorporated the correlation between sensitivity and specificity, using SAS software, version 9.3 (SAS Institute) (20). We assumed bivariate normal distributions for sensitivity and specificity. Statistical heterogeneity was measured with the random-effect variance ( 2 ). We calculated positive and negative likelihood ratios by using the summarized sensitivity and specificity (21, 22) .
We analyzed data separately for each imaging modality; ultrasonography with and without contrast were also analyzed separately. We also separately analyzed studies in which imaging was performed for detection of HCC and for evaluation of focal liver lesions; studies on HCC detection were further stratified by setting (surveillance or nonsurveillance). We separately analyzed test performance by using patients with HCC or by using HCC lesions (one patient can have multiple lesions) as the unit of analysis. Other sensitivity and subgroup analyses were conducted on the reference standard, factors related to risk of bias, country, technical factors (Appendix Table 2 ), tumor factors (such as HCC lesionSixty-eight studies evaluated ultrasonography (Appendix Table 3 ), 131 evaluated CT (25-153), and 125 evaluated MRI (Appendix Table 3 ). Almost all studies reported sensitivity, but specificity was available in only 139 studies.
We rated 5 studies as having low risk of bias (56, 99, 128, 132, 154), 199 as having moderate risk of bias, and 89 as having high risk of bias (13) . One hundred twenty-five studies avoided use of a case-control design, 160 used blinded design, and 75 were prospective. More studies were conducted in Asia (190 studies) than in Australia, Canada, the United States, or Europe (95 studies in total for these regions). In 166 studies, imaging began in or after 2003 (13) .
Twenty-eight studies evaluated CT using methods that met minimum technical specifications (≥8-row multidetector CT; contrast rate ≥3 mL/s; at least arterial, portal venous, and delayed-phase imaging; delayedphase imaging performed >120 s after administration of contrast; and enhanced imaging section thickness ≤5 mm), and 67 studies evaluated MRI using methods that met minimum technical specifications (1.5-or 3.0-T MRI; at least arterial, portal venous, and delayed-phase imaging; delayed-phase imaging performed >120 s after administration of contrast; and enhanced imaging section thickness ≤5 mm). Seventy-three MRI studies evaluated use of hepatic-specific contrast (for example, gadoxetic acid or gadobenate). Forty-seven ultrasonography studies evaluated use of microbubble contrast agents.
Six studies (34, 47, 134, 140, 155, 156) of imaging for detection of HCC were conducted in surveillance settings, and 191 studies were conducted in nonsurveillance settings. Fifty-six studies evaluated imaging for identification of HCC in patients with focal liver lesions.
Detection of HCC

Surveillance Settings
Few studies evaluated imaging for HCC in surveillance settings (strength of evidence, low to insufficient). Sensitivity of ultrasonography without contrast for HCC lesions was 0.78 (95% CI, 0.60 to 0.89; 4 studies) and specificity was 0.89 (CI, 0.80 to 0.94; 3 studies), for a positive likelihood ratio of 6.8 (CI, 4.2 to 11) and a negative likelihood ratio of 0.25 (CI, 0.13 to 0.46) ( Table 1 and Appendix Figure 2 , available at www.annals.org). For CT, 2 studies reported sensitivity of 0.84 (CI, 0.59 to 0.95) and specificity of 0.99 (CI, 0.86 to 0.999) (34, 140) . No study evaluated ultrasonography with contrast or MRI in surveillance settings.
Nonsurveillance Settings
Most studies on detection of HCC were performed in nonsurveillance settings (strength of evidence, low to moderate). The sensitivity of ultrasonography without contrast for identification of patients with HCC was 0.73 (CI, 0.46 to 0.90; 8 studies), and specificity was 0.93 (CI, 0.85 to 0.97; 6 studies) (Appendix Figure 3 , available at www.annals.org). For CT, sensitivity was 0.83 (CI, 0.75 to 0.89; 17 studies) and specificity was 0.91 (CI, 0.86 to 0.96; 11 studies) ( Figure 1 ).
For MRI, sensitivity was 0.86 (CI, 0.79 to 0.91; 14 studies) and specificity was 0.89 (CI 0.83 to 0.93; 12 studies) (Figure 2 ). Across modalities, positive likelihood ratios ranged from 7.7 to 11 and negative likelihood ratios from 0.16 to 0.29, with overlapping CIs (Table 1) . For ultrasonography without contrast, restricting the analysis to studies that avoided a case-control design decreased sensitivity (0.54 [CI, 0.38 to 0.70]; 6 studies). For CT, studies with a contrast rate of 3 mL/s or greater reported a higher sensitivity (0.86 [CI, 0.78 to 0.92]; 9 studies) than studies with a contrast rate less than 3 mL/s (0.71 [CI, 0.53 to 0.84]; 4 studies), and studies with delayed-phase imaging reported somewhat higher sensitivity (0.89 [CI, 0.81 to 0.94]; 7 studies) than studies without delayed-phase imaging (0.79 [CI, 0.68 to 0.87]; 8 studies).
The sensitivity of ultrasonography without contrast for HCC lesions was 0.59 (CI, 0.42 to 0.74; 11 studies), and specificity was 0.83 (CI, 0.53 to 0.95; 2 studies) (Appendix Figure 4 , available at www.annals.org). For ultrasonography with contrast, sensitivity was 0.75 (CI, 0.57 to 0.88; 9 studies); only 1 study reported specificity (Appendix Figure 5 , available at www.annals.org). In 7 of 9 studies, the ultrasonography contrast agent was perflubutane. For CT, sensitivity was 0.76 (CI, 0.72 to 0.80; 80 studies) and specificity was 0.90 (CI, 0.84 to 0.93; 21 studies) (Appendix Figure 6 , available at www .annals.org). For MRI, sensitivity was 0.83 (CI, 0.80 to 0.86; 82 studies) and specificity was 0.88 (CI, 0.79 to 0.93; 20 studies) (Appendix Figure 7 , available at www .annals.org). The likelihood ratios were somewhat weaker for ultrasonography without contrast (positive likelihood ratio, 3.4 [CI, 1.2 to 9.4]; negative likelihood ratio, 0.50 [CI, 0.37 to 0.66]) than for CT or MRI (positive likelihood ratios, 7.1 and 6.5; negative likelihood ratios, 0.26 and 0.20, respectively). (157-164)
Direct Comparisons
Within-study comparisons provide more direct evidence on comparative test performance (strength of evidence, moderate). Two studies that directly compared ultrasonography with versus without contrast in nonsurveillance settings found no difference in sensitivity for detection of HCC lesions (difference, Ϫ0.04 [CI, Ϫ0.11 to 0.04]) (Table 2) (165, 166).
Sensitivity was lower for ultrasonography without contrast than CT or MRI. Compared with CT, the difference in sensitivity for HCC lesions was Ϫ0.11 (CI, Ϫ0.17 to Ϫ0.04; 3 studies); compared with MRI, the difference was Ϫ0.22 (CI, Ϫ0.31 to Ϫ0.14; 3 studies). Findings were similar for identification of patients with HCC.
Ultrasonography with contrast was also associated with lower sensitivity than CT (difference, Ϫ0.16 [CI, Ϫ0.32 to Ϫ0.01]; 3 studies). The difference between the sensitivity of ultrasonography with contrast and that of MRI was smaller and not statistically significant (Ϫ0.08 [CI, Ϫ0.19 to 0.02]; 3 studies).
When HCC lesions were used as the unit of analysis, MRI was associated with higher sensitivity for HCC Two studies of ultrasonography with contrast versus CT were performed in surveillance settings and reported results that were consistent with the overall findings (34, 140). Other direct comparisons of imaging modalities were performed in nonsurveillance settings.
In trials of MRI that directly compared test performance using different contrast agents, use of hepaticspecific contrast agents (gadoxetic acid or gadobenate) was associated with higher sensitivity than non-hepatic-specific contrast agents (gadopentetate or gadodiamide) (difference, 0.13 [CI, 0.07 to 0.18]; 9 studies), with no difference in specificity. The difference was somewhat greater for HCC lesions smaller than 2 cm (difference, 0.15 [CI, 0.08 to 0.22]; 7 studies). There was no difference in sensitivity between MRI with diffusion-weighted and contrast-enhanced imaging and contrast-enhanced MRI without diffusion-weighted imaging for HCC lesions, including lesions smaller than 2 cm.
One trial found no clear difference between the test performance of spectral versus standard CT (101).
Evaluation of Focal Liver Lesions
For evaluation of focal liver lesions, strength of evidence ranged from low to moderate. Sensitivity of ultrasonography with contrast for identification of patients with HCC was 0.87 (CI, 0.79 to 0.92; 12 studies), and specificity was 0.92 (CI, 0.83 to 0.95; 8 studies) (Appendix Figure 8 , available at www.annals.org). For CT, sensitivity was 0.86 (CI, 0.75 to 0.92; 8 studies) and specificity was 0.88 (CI, 0.76 to 0.95; 5 studies) (Appendix Figure 9 , available at www.annals.org). For MRI, sensitivity was 0.75 (CI, 0.65 to 0.83; 5 studies) and specificity was 0.83 (CI, 0.61 to 0.93; 5 studies) (Appendix Figure 10 , available at www.annals.org). The positive likelihood ratio was somewhat stronger for ultrasonography with contrast (9.6 [CI, 5.1 to 18]) than for CT or MRI (7.4 and 4.1, respectively); the negative likelihood ratio ranged from 0.14 to 0.31 ( Table 1) .
Sensitivity of ultrasonography with contrast for HCC lesions was 0.87 (CI, 0.80 to 0.92; 23 studies), and specificity was 0.91 (CI, 0.85 to 0.95; 11 studies) (Appendix Figure 11 , available at www.annals.org). For CT, sensitivity was 0.79 (CI, 0.67 to 0.87; 13 studies) and specificity was 0.90 (CI, 0.37 to 0.99; 6 studies) (Appendix Figure 12 , available at www.annals.org). For MRI, sensitivity was 0.81 (CI, 0.73 to 0.88; 15 studies) and specificity was 0.92 (CI, 0.78 to 0.97; 12 studies) (Appendix Figure 13 , available at www.annals.org). Across modalities, the positive likelihood ratio ranged from 7.7 to 10 and the negative likelihood ratio from 0.14 to 0.24, with overlapping CIs. 
Direct Comparisons
Two studies found ultrasonography with contrast to be associated with higher sensitivity than ultrasonography without contrast (difference, 0.50 [CI, 0.41 to 0.58]) ( 
Effects of a Reference Standard
Across imaging modalities, sensitivity was lower when an explanted liver was used as the reference standard than when other reference standards were used (Appendix Table 4 , available at www.annals.org; strength of evidence, moderate). The difference was more pronounced for ultrasonography with contrast (sensitivity for HCC lesions, 0.34 with explanted liver vs. 0.72 to 0.75 with other reference standards) and less pronounced for CT and MRI (sensitivity, 0.67 and 0.70, respectively, for explanted liver and 0.80 to 0.88 for other reference standards). A similar pattern was observed for ultrasonography without contrast when patients with HCC lesions were used as the unit of analysis.
Effects of Patient and Tumor Characteristics
Across imaging modalities, sensitivity increased with larger tumor sizes (Appendix Table 5 , available at www.annals.org; strength of evidence, moderate). Differences in sensitivity for lesions larger than 20 mm versus those 10 to 20 mm ranged from 0.17 to 0.37; for lesions 10 to 20 mm versus those smaller than 10 mm, differences in sensitivity ranged from 0.28 to 0.42. Sensitivity was also higher for moderately or poorly differentiated versus well-differentiated tumors (difference, 0.34 to 0.40).
Effects of other tumor characteristics and patient factors on test performance were not well-studied (strength of evidence, insufficient to low). For ultrasonography, lesion depth and body mass index had no effect on estimates of sensitivity (169 -171). For MRI, 3 
DISCUSSION
The key findings of this review, including detailed strength of evidence grades, are summarized in Appendix Table 6 (available at www.annals.org). For detection of HCC, too few studies were conducted in surveillance settings to draw strong conclusions, although 2 head-to-head studies found that ultrasonography without contrast had lower sensitivity than CT (34, 140). In nonsurveillance settings, on the basis of within-study comparisons, sensitivity for HCC lesions was lower for ultrasonography without contrast than for CT or MRI (difference, 0.11 to 0.22) and sensitivity of MRI was higher than that of CT (difference, 0.09 [CI 0.07 to 12]). There were no differences between ultrasonography with versus without contrast for detection of HCC in patients not undergoing evaluation of focal liver lesions (165, 166); this finding is consistent with the short duration that microbubble contrast is present within the liver (12) . For evaluation of focal liver lesions, there were no clear differences in sensitivity among ultrasonography with contrast, CT, and MRI, except that ultrasonography with contrast was associated with lower sensitivity than MRI for small HCC lesions.
Across imaging modalities, specificity was generally 0.85 or higher, but many studies did not report specificity and pooled estimates were frequently imprecise. Most likelihood ratios were in or near the "moderately useful" range (positive likelihood ratio of 5 to 10 and negative likelihood ratio of 0.1 to 0.2) (174).
Across imaging modalities, factors associated with lower estimates of sensitivity were an explanted liver as the reference standard, HCC lesions (rather than patients with HCC) as the unit of analysis, and smaller or more well-differentiated HCC lesions. For CT, higher contrast rates and use of delayed-phase imaging were associated with higher sensitivity in subgroup analyses. For MRI, within-study comparisons found hepaticspecific contrast agents to be associated with slightly higher sensitivity than non-hepatic-specific contrast agents, particularly for smaller lesions. Other sensitivity and stratified analyses, including analyses based on technical factors, resulted in no clear differences.
Our findings differ from those of previously published reviews that found no clear differences in test performance among ultrasonography, CT, and MRI (175) (176) (177) (178) . Some features of our review that might explain these discrepancies include inclusion of more studies, and performance of separate analyses based on reason for imaging and unit of analysis. In addition, we found differences in the sensitivity of imaging modalities for detection of HCC in direct (within-study) comparisons that were not observed in indirect (acrossstudy) comparisons. This is consistent with research showing that results of diagnostic test reviews based on direct comparisons often differ from those of reviews based on indirect comparisons (23) . Some factors might affect the applicability of our findings. Over one half of the studies were conducted in Asia, although stratification of studies by country had no clear effects on estimates. Some studies excluded nonhypervascular HCC lesions, but estimates were similar when we excluded such studies. Because imaging techniques are evolving, we restricted our review to studies published since 1998 and to imaging methods that met minimal technical criteria, and performed additional sensitivity and subgroup analyses on technical factors. Almost all studies on detection of HCC were performed in nonsurveillance settings, most of which evaluated high-prevalence populations.
Our review has limitations. Substantial statistical heterogeneity was present in most pooled analyses-a situation common in meta-analyses of diagnostic accuracy (179 -181) . Because of anticipated heterogeneity, we used a random-effects model to pool studies, performed stratified and subgroup analyses, and performed separate analyses based on within-study comparisons. In addition, we restricted inclusion to Englishlanguage articles and did not formally assess for publication bias by using statistical or graphical methods for small sample effects, because such methods can be misleading for diagnostic studies (182, 183) . We did not identify unpublished studies through searches on clinical trial registries and regulatory documents, although the usefulness of such methods for diagnostic studies may be limited.
Although test performance can provide useful information about the accuracy of diagnostic tests (Appendix Table 7 , available at www.annals.org), the effects on clinical outcomes depend on whether they lead to more optimal use of effective interventions, balanced against harms from performing the test or subsequent tests and interventions. As described in the full report (13) , the only study on the effects of surveillance (with ultrasonography and ␣-fetoprotein) versus no surveillance on clinical outcomes found a decreased risk for liver-specific mortality, but it was conducted in China and had methodological shortcomings (184) . No study measured downstream harms related to falsepositive or false-negative test results, anxiety or labeling due to imaging, or subsequent work-up after imaging. Although the risk for serious imaging-related direct harms appears to be low (185) (186) (187) (188) , potential harms include serious cardiopulmonary events with microbubble contrast agents (189 -191) and long-term effects of radiation exposure with CT (192) . Factors other than test performance, such as convenience or cost, that depend on the imaging modality and specific technical factors (such as the type of contrast and imaging machine), frequency of imaging, and need for follow-up testing, may also affect the choice of imaging modalities and techniques.
In conclusion, CT and MRI are associated with higher sensitivity than ultrasonography without contrast for detection of HCC; sensitivity is higher for MRI than for CT. For evaluation of focal liver lesions, the sensitivities of ultrasonography with contrast, CT, and MRI for HCC seem to be similar. Across imaging modalities, sensitivity was low for small and well-differentiated lesions. Research is needed to understand the effects of test performance differences on clinical outcomes. Nonclinical and nondiagnostic outcomes CT = computed tomography; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; MRI = magnetic resonance imaging; PET = positron emission tomography. Reference numbers are those in Appendix Table 3 . 
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